Acceleron Pharma (XLRN) Tops Q1 EPS by 6c

Acceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.58), $0.06 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.23 million versus the consensus estimate of $4.21 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Pony AI (PONY) Reports Revenue Above Estimates
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance